News
Public · Published
Ultragenyx Pharma Price Target Raised to $19.00/Share From $18.00 by TD Cowen
TD Cowen raised its price target for Ultragenyx Pharma to $19.00 per share from $18.00 per share. The accompanying ratings notice says TD Cowen maintained its Buy rating on the company.
Published:
Updated:
What happened
TD Cowen raised its price target for Ultragenyx Pharma to $19.00 per share from $18.00 per share. The accompanying ratings notice says TD Cowen maintained its Buy rating on the company.
Confirmed
Global impact / market context
A higher price target signals that TD Cowen sees more potential value in Ultragenyx shares than before, while keeping its Buy rating. The change could influence investor expectations, but it does not itself change the company’s revenue, costs, or cash available.
Analyst inference
The update is an analyst opinion rather than a reported change in Ultragenyx’s business or financial results. Since the Buy rating was maintained, the new information is the higher target; the supplied notice gives no rationale or forecast details behind it.
Confirmed
What to watch
- Watch for any further analyst updates that explain the higher target or change the Buy rating; the supplied notice does not state why TD Cowen raised it. Analyst inference
- Look for Ultragenyx business or financial updates that could clarify whether operating results support the higher valuation implied by TD Cowen’s target. Analyst inference
- The notice reports a $19.00-per-share target, up from $18.00, and says TD Cowen maintained its Buy rating. Confirmed
Evidence
- Original source link unavailable